Kirkland Advises Cinven on Squeeze-Out of SYNLAB

Kirkland & Ellis has advised Cinven on the squeeze-out of minority shareholders of SYNLAB AG. The corporate squeeze-out of the minority shareholders was approved by the general meeting and was completed in July 2025.

SYNLAB AG is one of the leading European clinical laboratory and medical diagnostic services companies and has more than 24,000 employees in over 20 countries across four continents. The company achieved revenues of EUR 2.62 billion in 2024.

Kirkland had already advised Cinven on the public acquisition offer for all outstanding shares of SYNLAB AG, the subsequent delisting offer as well as the sale of an indirect minority stake to Labcorp and the reinvestment of Elliott.

The Kirkland team included corporate lawyers Achim Herfs, Thomas Hornberger and Sabrina Seitz.